3. Long-Acting Two-Drug Injectable HIV Regimen Proves Successful in Phase 2 Trial
After a total of 96 weeks of maintenance treatment, the viral suppression rates were shown to be 94% for the 2-drug regimen at dosing every 8 weeks, and 87% for dosing every 4 weeks. These results were comparable to those observed for patients on a 3-drug oral regimen (84%). Of note: “2 patients in the 8-week dosing group and 1 patient in the oral regimen group met protocol-defined virologic failure criteria; neither patient had evidence of resistance at failure,” according to the press release. Pain at the injection site was the “most commonly reported injection site reaction (ISR) reported by patients receiving injectable cabotegravir 2 and rilpivirine.”
“These study results are important because we now have data showing the durability and tolerability of long-acting viral suppression for a two-drug regimen out to 96 weeks. Administration of long-acting parenteral medication removes the daily dosing burden for patients and the LATTE-2 results showed that long-acting cabotegravir and rilpivirine maintained viral suppression, with no virologic failures in the four-week dosing group. We look forward to results from our phase 3 program with long-acting cabotegravir and rilpivirine in 2018,” stated John C Pottage Jr, Chief Scientific and Medical Officer for ViiV Healthcare in the press release.
Learn more about the new long-acting two-drug HIV regimen, here
2. Taking A Closer Look at Humanized Monoclonal Antibody PRO 140 for HIV Treatment
The efficacy results from 1 of 2 PRO 140 clinical trials should be announced in the next month, according to CytoDyn. What Dr. Pourhassan projects is a once-weekly subcutaneous self-injection antibody that protects healthy cells from HIV infection by binding to the C-C chemokine receptor type 5 (CCR5).
CCR5 is a white blood cell surface protein used by the virus to infect host cells. Paul J. Maddon, MD, PhD, the inventor of PRO 140, was credited by Dr. Pourhassan as one of the forefront researchers in CCR5’s role in HIV treatment for the past decade.
In previous trials, PRO 140 has been shown to reduce HIV viral load in the body, while maintaining a long-term reduction, according to CytoDyn. Patients observed in such trials have been on the treatment for over 2 years during the study’s extension, and have reported minimal adverse effects and toxicities—and no viral resistance.
Read more about humanized monoclonal antibody PRO 140 for HIV, here